Novo Nordisk is facing intensified focus on its rivalry with Eli Lilly in the obesity drug market, according to analysis from August 3, 2026. Investor confidence is reportedly now heavily dependent on the success of its new Wegovy weight-loss pill as it competes with Lilly's Foundayo. Analysts suggest that after a difficult period, the company may need to pursue strategic deals to bolster its long-term competitive position in the obesity sector.
This analysis follows a significant recent setback. On July 31, the company's stock fell sharply after its experimental cardiovascular drug, ziltivekimab, failed in a late-stage trial. The failure has increased pressure on Novo's core obesity and diabetes portfolio. While analysts note the trial failure is a disappointment, the primary focus remains on the company's ability to compete and innovate within its main therapeutic areas against key rivals.